WebMar 15, 2024 · F-star Therapeutics Reports Full-Year 2024 Financial Results and Provides Corporate Update . Multiple Clinical Program Updates Expected in 2024 . ... Ticker: FSTX CIK: 1566373 Form Type: 10-K Annual Report Accession Number: 0000950170-22-003650 Submitted to the SEC: Tue Mar 15 2024 7:06:24 AM EST WebMar 9, 2024 · F-star Therapeutics, Inc. (NASDAQ:FSTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.52) earnings per …
Home - F-Star Therapeutics Inc.
WebF-Star Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on advanced pipeline of multiple immuno-oncology programs … WebF-star’s robust, proprietary clinical pipeline includes three tetravalent mAb2 bispecific programs designed for focused, potent and safe immune activation.In addition, F-star has an intravenously administered, next generation STING agonist, SB 11285, in clinical trials. Each directed against some of the most promising IO targets in drug development, there … family resorts mexico
Fstar Therapeutics, Inc. (FSTX) 10K Annual Reports & 10Q SEC …
WebMar 3, 2024 · F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing immunotherapies to transform the lives of patients with cancer. The Company's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing FS222, FS120 ... Web1 day ago · During the first quarter of 2024, a total of $46.7 million of loans funded through the Horizon Platform, including eight loans totaling $40.2 million funded by HRZN as follows: $20.0 million to a new portfolio company, an education technology company building an online and lifelong knowledge network of universities, corporations and learners. WebDec 29, 2024 · Shares of F-star Therapeutics Inc. plunged 38.3% to $4.23 in premarket trading after the company said a U.S. national security committee blocked its merger with a unit of Sino Biopharmaceutical Ltd. cooling lens filter